Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin - PubMed (original) (raw)
Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin
T Kitamura et al. J Cell Physiol. 1989 Aug.
Abstract
We have established a novel cell line, designated as TF-1, from a patient with erythroleukemia, which showed complete growth dependency on granulocyte-macrophage colony-stimulating factor (GM-CSF) or on interleukin-3 (IL-3) and carried a homogeneous chromosomal abnormality (54X). Erythropoietin (EPO) also sustained the short-term growth of TF-1, but did not induce erythroid differentiation. These three hematopoietic growth factors acted on TF-1 synergistically. Transforming growth factor-beta and interferons inhibited the factor-dependent growth of TF-1 cells in a dose-dependent fashion, and monocyte-colony stimulating factor and interkeukin-1 enhanced the GM-CSF-dependent growth of TF-1. Ultrastructural studies revealed some very immature features in this cell line. Although TF-1 cells do not express glycophorin A or carbonyl anhydrase I, the morphological and cytochemical features, and the constitutive expression of globin genes, indicate the commitment of TF-1 to erythroid lineage. When induced to differentiate, TF-1 entered two different pathways. Specifically, hemin and delta-aminolevulinic acid induced hemoglobin synthesis, whereas TPA induced dramatic differentiation of TF-1 into macrophage-like cells. In summary, TF-1 is a cell line of immature erythroid origin that requires GM-CSF, IL-3, or EPO for its growth and that has the ability to undergo differentiation into either more mature erythroid cells or into macrophage-like cells. TF-1 is a useful tool for analyzing the human receptors for IL-3, GM-CSF, and EPO or the signal transduction of these hemopoietic growth factors.
Similar articles
- Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1.
Kitamura T, Tojo A, Kuwaki T, Chiba S, Miyazono K, Urabe A, Takaku F. Kitamura T, et al. Blood. 1989 Feb;73(2):375-80. Blood. 1989. PMID: 2537111 - Establishment and erythroid differentiation of a cytokine-dependent human leukemic cell line F-36: a parental line requiring granulocyte-macrophage colony-stimulating factor or interleukin-3, and a subline requiring erythropoietin.
Chiba S, Takaku F, Tange T, Shibuya K, Misawa C, Sasaki K, Miyagawa K, Yazaki Y, Hirai H. Chiba S, et al. Blood. 1991 Nov 1;78(9):2261-8. Blood. 1991. PMID: 1834251 - In polycythemia vera human interleukin 3 and granulocyte-macrophage colony-stimulating factor enhance erythroid colony growth in the absence of erythropoietin.
de Wolf JT, Beentjes JA, Esselink MT, Smit JW, Halie RM, Clark SC, Vellenga E. de Wolf JT, et al. Exp Hematol. 1989 Oct;17(9):981-3. Exp Hematol. 1989. PMID: 2673832 - Granulocyte-macrophage colony-stimulating factor and erythropoietin act competitively to induce two different programs of differentiation in the human pluripotent cell line UT-7.
Hermine O, Mayeux P, Titeux M, Mitjavila MT, Casadevall N, Guichard J, Komatsu N, Suda T, Miura Y, Vainchenker W, et al. Hermine O, et al. Blood. 1992 Dec 15;80(12):3060-9. Blood. 1992. PMID: 1467515
Cited by
- Silencing of the DNA damage repair regulator PPP1R15A sensitizes acute myeloid leukemia cells to chemotherapy.
Bouchla A, Sotiropoulou CD, Esteb C, Loupis T, Papageorgiou SG, Deliconstantinos GG, Pagoni M, Hatzimichael E, Dellatola M, Kalomoiri S, Apostolidou E, Kontos CK, Thomopoulos TP, Karantanos T, Pappa V. Bouchla A, et al. Ann Hematol. 2024 Aug;103(8):2853-2863. doi: 10.1007/s00277-024-05785-x. Epub 2024 Jun 6. Ann Hematol. 2024. PMID: 38842564 Free PMC article. - CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant Cells.
Waarts MR, Mowla S, Boileau M, Martinez Benitez AR, Sango J, Bagish M, Fernández-Maestre I, Shan Y, Eisman SE, Park YC, Wereski M, Csete I, O'Connor K, Romero-Vega AC, Miles LA, Xiao W, Wu X, Koche RP, Armstrong SA, Shih AH, Papapetrou EP, Butler JM, Cai SF, Bowman RL, Levine RL. Waarts MR, et al. Cancer Discov. 2024 Oct 4;14(10):1860-1878. doi: 10.1158/2159-8290.CD-23-1092. Cancer Discov. 2024. PMID: 38819218 - IDH2/R140Q mutation confers cytokine-independent proliferation of TF-1 cells by activating constitutive STAT3/5 phosphorylation.
Yang J, Chen J, Chang J, Sun X, Wei Q, Cai X, Cao P. Yang J, et al. Cell Commun Signal. 2024 Feb 12;22(1):116. doi: 10.1186/s12964-023-01367-y. Cell Commun Signal. 2024. PMID: 38347540 Free PMC article. - Treatment of Parkinson's disease with biologics that penetrate the blood-brain barrier via receptor-mediated transport.
Pardridge WM. Pardridge WM. Front Aging Neurosci. 2023 Nov 13;15:1276376. doi: 10.3389/fnagi.2023.1276376. eCollection 2023. Front Aging Neurosci. 2023. PMID: 38035276 Free PMC article. Review. - Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells.
Morishima T, Takahashi K, Chin DWL, Wang Y, Tokunaga K, Arima Y, Matsuoka M, Suda T, Takizawa H. Morishima T, et al. Cancer Sci. 2024 Jan;115(1):197-210. doi: 10.1111/cas.15994. Epub 2023 Oct 26. Cancer Sci. 2024. PMID: 37882467 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous